Competitor Analysis: Erythropoietin (EPO)
Product description
The Competitive Intelligence Report Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) as of January 2011 in its 5th edition provides information on existing first and second generation epoetin products in regulated markets, an overview on biosimilar versions of EPO in regulated markets, a compilation of novel, next generation Erythropoiesis Stimulating Agents (ESAs) separately for biologics and for oral small molecules and a summary of first generation EPO products as well as of darbepoietin biosimilar versions in less regulated markets.
Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently marketed Erythropoieitin (EPO) & Erythropoiesis Stimulating Agents (ESA) products and active EPO and ESA projects in research and development. In addition, the report lists company-specific product portfolios and R&D pipelines of Erythropoieitin (EPO) & Erythropoiesis Stimulating Agents (ESA) on the market or in R&D. Competitor projects are listed in a tabular format providing Information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product category/Therapeutic Area,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Index
First generation epoetins in regulated markets
Second generation epoetins in regulated markets
EPO biosimilars in regulated markets
Next generation biologic Eythropoiesis Stimulating Agents
Next generation small molecule Erythropoiesis Stimulating Agents
First generation EPO in less regulated markets
Central & South America
Africa
Asia
Rest of the World
Darbepoietin biosimilars in less regulated markets
Corporate EPO & ESA Product Portfolios & R&D Pipelines
Acceleron Pharma
Ach? Laborat?rios Farmac?uticos S/A
Affymax
Akebia Therapeutics
Amega Biotech
Amgen
Amoun Pharmaceuticals
Antyra Biotechnology
Astellas
Axxo Mexico
Barr Pharmaceuticals
Baxter
Bayer Schering Pharma
Bio-Manguinhos
Bio-Sidus
Bioceuticals
Bioclones
Biocon Biopharmaceuticals
Biofarma
BioGeneric Pharma
Biorelm
Blausiegel Industria e Comercio
Bolder Biotechnology
Boryung
Celgene
Chengu Di'ao Pharmaceutical Company
Chugai
CIMAB
CinnaGen
CJ Corporation
Claris Lifesciences
Cristalia Produtos Quimicos Farmaceuticos Ltd
Cryopharma
DNAPrint Genomics
Dong-A Pharmaceutical
DPS Medical Co.
Dr Reddy's
Dragon Pharmaceuticals
Edison Pharmaceuticals
Eipico
Emcure Biotech
Eurofarma Laboratorios
Fibrogen
Genexine Co
GlaxoSmithKline (GSK)
Glycode
Green Cross
Hanmi Pharmaceutial
Heber Biotec
Hindustan Antibiotics
Hindustan Bio Sciences
Hospira
Instituto Butantan
Intas Pharmaceuticals
J&J (Centocor)
JCR Pharmaceuticals
Kissei Pharmaceuticals
KunWha Pharmaceutical Co
Kyowa Hakko Kirin Pharma
Laboratorio Elea
Laboratorio Quimico e Farmaceutico Bergamo
Laboratorios Pisa
Lentigen
Lessel
LG Chemicals India
LG Life Science
Ligand Pharmaceuticals
Lipoxen
MedExGen
Medgenics
Medice
MultiMedica
Nanogen Biopharmaceutical
NCPC GeneTech Biotech Dev.
North China Pharmaceutical Group Corporation
Ortho Biotech
Palkion
PharmaEssentia
PolyTherics Limited
Probiomed
Prolong Pharmaceuticals
PROLOR Biotech
ProMetic Life Sciences
Protein Sciences
Ranbaxy
Reliance GeneMedix
Reliance Life Sciences
Roche
Sandoz
SciGen
ScinoPharm Biotech
Sedico
Serum Institute of India
Shamrock Industrial Co
Shantha Biotechnics
Shenyang Sunshine Pharmaceutical Corporation
Shenzen Inter-Chemical
Silvestre Laboratorio Quimico e Farmaceutico
SinoBio Biotech
SK Chemicals
Sudershan Biotech
T3A Pharma
Takeda
Tanvex Biologics
Therapeutic Proteins Inc
Transgene Biotek
Uni-Bio Science
Wockhardt
Xiamen Amoytop Biotech
XTL Biopharmaceuticals
Zenotech Laboratories
Zydus Cadila
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) as of January 2011 in its 5th edition provides information on existing first and second generation epoetin products in regulated markets, an overview on biosimilar versions of EPO in regulated markets, a compilation of novel, next generation Erythropoiesis Stimulating Agents (ESAs) separately for biologics and for oral small molecules and a summary of first generation EPO products as well as of darbepoietin biosimilar versions in less regulated markets.
Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently marketed Erythropoieitin (EPO) & Erythropoiesis Stimulating Agents (ESA) products and active EPO and ESA projects in research and development. In addition, the report lists company-specific product portfolios and R&D pipelines of Erythropoieitin (EPO) & Erythropoiesis Stimulating Agents (ESA) on the market or in R&D. Competitor projects are listed in a tabular format providing Information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product category/Therapeutic Area,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Index
First generation epoetins in regulated markets
Second generation epoetins in regulated markets
EPO biosimilars in regulated markets
Next generation biologic Eythropoiesis Stimulating Agents
Next generation small molecule Erythropoiesis Stimulating Agents
First generation EPO in less regulated markets
Central & South America
Africa
Asia
Rest of the World
Darbepoietin biosimilars in less regulated markets
Corporate EPO & ESA Product Portfolios & R&D Pipelines
Acceleron Pharma
Ach? Laborat?rios Farmac?uticos S/A
Affymax
Akebia Therapeutics
Amega Biotech
Amgen
Amoun Pharmaceuticals
Antyra Biotechnology
Astellas
Axxo Mexico
Barr Pharmaceuticals
Baxter
Bayer Schering Pharma
Bio-Manguinhos
Bio-Sidus
Bioceuticals
Bioclones
Biocon Biopharmaceuticals
Biofarma
BioGeneric Pharma
Biorelm
Blausiegel Industria e Comercio
Bolder Biotechnology
Boryung
Celgene
Chengu Di'ao Pharmaceutical Company
Chugai
CIMAB
CinnaGen
CJ Corporation
Claris Lifesciences
Cristalia Produtos Quimicos Farmaceuticos Ltd
Cryopharma
DNAPrint Genomics
Dong-A Pharmaceutical
DPS Medical Co.
Dr Reddy's
Dragon Pharmaceuticals
Edison Pharmaceuticals
Eipico
Emcure Biotech
Eurofarma Laboratorios
Fibrogen
Genexine Co
GlaxoSmithKline (GSK)
Glycode
Green Cross
Hanmi Pharmaceutial
Heber Biotec
Hindustan Antibiotics
Hindustan Bio Sciences
Hospira
Instituto Butantan
Intas Pharmaceuticals
J&J (Centocor)
JCR Pharmaceuticals
Kissei Pharmaceuticals
KunWha Pharmaceutical Co
Kyowa Hakko Kirin Pharma
Laboratorio Elea
Laboratorio Quimico e Farmaceutico Bergamo
Laboratorios Pisa
Lentigen
Lessel
LG Chemicals India
LG Life Science
Ligand Pharmaceuticals
Lipoxen
MedExGen
Medgenics
Medice
MultiMedica
Nanogen Biopharmaceutical
NCPC GeneTech Biotech Dev.
North China Pharmaceutical Group Corporation
Ortho Biotech
Palkion
PharmaEssentia
PolyTherics Limited
Probiomed
Prolong Pharmaceuticals
PROLOR Biotech
ProMetic Life Sciences
Protein Sciences
Ranbaxy
Reliance GeneMedix
Reliance Life Sciences
Roche
Sandoz
SciGen
ScinoPharm Biotech
Sedico
Serum Institute of India
Shamrock Industrial Co
Shantha Biotechnics
Shenyang Sunshine Pharmaceutical Corporation
Shenzen Inter-Chemical
Silvestre Laboratorio Quimico e Farmaceutico
SinoBio Biotech
SK Chemicals
Sudershan Biotech
T3A Pharma
Takeda
Tanvex Biologics
Therapeutic Proteins Inc
Transgene Biotek
Uni-Bio Science
Wockhardt
Xiamen Amoytop Biotech
XTL Biopharmaceuticals
Zenotech Laboratories
Zydus Cadila
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
